Citations

Showing 10 of 108104 citations.

Weight gain trajectories during outpatient family‐based treatment for adolescents with anorexia nervosa
Lebow, Jocelyn , Sim, Leslie , Goldschmidt, Andrea B. , Grange, Daniel Le , Accurso, Erin C. , Goldschmidt, Andrea B , Le Grange, Daniel , Accurso, Erin C , Lebow, Jocelyn , Crosby, Ross D.

Mayo Clinic

International Journal of Eating Disorders | December 22, 2018 | Volume: 52 | Issue: 1 | Pages: 88-94

10.1002/eat.23000 | PMID 30578648 Get It

AbstractObjectiveGiven that weight gain patterns in adolescents receiving outpatient Family‐Based Treatment (FBT) have not been characterized, the purpose of this study was to examine trajectories of weight gain in a group of adolescent patients with a restrictive eating disorder [e.g., anorexia nervosa (AN) and atypical AN] receiving FBT. This study also examined the association of patient characteristics with weight gain trajectories, including age, diagnosis, weight suppression, presenting BMI‐for‐age percentile, and eating pathology.MethodLatent growth mixture modeling was used to identify distinct weight trajectories, as defined by change in BMI‐for‐age percentile, for 153 adolescents with AN or atypical AN, receiving FBT.ResultsThere were five distinct weight gain trajectory profiles for adolescents receiving FBT for a restrictive eating disorder. Younger age and greater weight suppression were associated with more rapid weight gain trajectories. A pattern of slow and consistent weight gain was associated with older age and less eating pathology.DiscussionThere was considerable variability in weight gain trajectories in youth receiving outpatient FBT for a restrictive eating disorder. This suggests that patients' presenting information can be used to inform expectations regarding weight gain trajectories.
Manipulation of mechanical ventilatory constraint during moderate intensity exercise does not influence dyspnoea in healthy older men and women
Molgat‐Seon, Yannick , Ramsook, Andrew H. , Peters, Carli M. , Schaeffer, Michele R. , Dominelli, Paolo B. , Romer, Lee M. , Road, Jeremy , Guenette, Jordan A. , Sheel, A. William , Ramsook, Andrew H

Mayo Clinic

The Journal of Physiology | December 22, 2018 | Volume: 597 | Issue: 5 | Pages: 1383-1399

10.1113/jp277476 | PMID 30578651 Get It

Key points The perceived intensity of exertional breathlessness (i.e. dyspnoea) is higher in older women than in older men, possibly as a result of sex‐differences in respiratory system morphology. During exercise at a given absolute intensity or minute ventilation, older women have a greater degree of mechanical ventilatory constraint (i.e. work of breathing and expiratory flow limitation) than their male counterparts, which may lead to a greater perceived intensity of dyspnoea. Using a single‐blind randomized study design, we experimentally manipulated the magnitude of mechanical ventilatory constraint during moderate‐intensity exercise at ventilatory threshold in healthy older men and women. We found that changes in the magnitude of mechanical ventilatory constraint within the physiological range had no effect on dyspnoea in healthy older adults. When older men and women perform moderate intensity exercise, mechanical ventilatory constraint does not contribute significantly to the sensation of dyspnoea. AbstractWe aimed to determine the effect of manipulating mechanical ventilatory constraint during submaximal exercise on dyspnoea in older men and women. Eighteen healthy subjects (aged 60–80 years; nine men and nine women) completed two days of testing. On day 1, subjects were assessed for pulmonary function and performed a maximal incremental cycle exercise test. On day 2, subjects performed three 6‐min bouts of cycling at ventilatory threshold, in a single‐blind randomized manner, while breathing: (i) normoxic helium‐oxygen (HEL) to reduce the work of breathing (Wb) and alleviate expiratory flow limitation (EFL); (ii) through an inspiratory resistance (RES) of ∼5 cmH2O L−1 s−1 to increase Wb; and (iii) ambient air as a control (CON). Oesophageal pressure, diaphragm electromyography, and sensory responses (category‐ratio 10 Borg scale) were monitored throughout exercise. During the HEL condition, there was a significant decrease in Wb (men: –21 ± 6%, women: –17 ± 10%) relative to CON (both P < 0.01). Moreover, if EFL was present during CON (four men and five women), it was alleviated during HEL. Conversely, during the RES condition, Wb (men: 42 ± 19%, women: 50 ± 16%) significantly increased relative to CON (both P < 0.01). There was no main effect of sex on Wb (P = 0.59). Across conditions, women reported significantly higher dyspnoea intensity than men (2.9 ± 0.9 vs. 1.9 ± 0.8 Borg scale units, P < 0.05). Despite significant differences in the degree of mechanical ventilatory constraint between conditions, the intensity of dyspnoea was unaffected, independent of sex (P = 0.46). When older men and women perform moderate intensity exercise, mechanical ventilatory constraint does not contribute significantly to the sensation of dyspnoea.
Strengthening the Interaction of the Virology Community with the International Committee on Taxonomy of Viruses (ICTV) by Linking Virus Names and Their Abbreviations to Virus Species
Calisher, Charles H. , Brister, J. Rodney , Fulhorst, Charles F., Haddow, Andrew D. , Hyndman, Timothy H. , Junglen, Sandra , Klempa, Boris , Klingström, Jonas , LaBeaud, A. Desirée , Nunes, Márcio Roberto Teixeira , Payne, Susan , Radoshitzky, Sheli R. , Rubbenstroth, Dennis , Sabanadzovic, Sead , Sasaya, Takahide , Varsani, Arvind , Wahl‐Jensen, Victoria , Zerbini, F. Murilo , Kuhn, Jens H. , Briese, Thomas , Charrel, Rémi N. , Dürrwald, Ralf , Ebihara, Hideki , Gao, George F. , Groschup, Martin H. , Kropinski, Andrew M. , Krupovìč, Mart , Maes, Piet , Nowotny, Norbert R. , Stenglein, Mark D. , Weaver, Scott C , Vasilakis, Nikos

Mayo Clinic

Systematic Biology | December 22, 2018 | Volume: 68 | Issue: 5 | Pages: 828-839

10.1093/sysbio/syy087 | PMID 30597118 Get It

AbstractThe International Committee on Taxonomy of Viruses (ICTV) is tasked with classifying viruses into taxa (phyla to species) and devising taxon names. Virus names and virus name abbreviations are currently not within the ICTV’s official remit and are not regulated by an official entity. Many scientists, medical/veterinary professionals, and regulatory agencies do not address evolutionary questions nor are they concerned with the hierarchical organization of the viral world, and therefore, have limited use for ICTV-devised taxa. Instead, these professionals look to the ICTV as an expert point source that provides the most current taxonomic affiliations of viruses of interests to facilitate document writing. These needs are currently unmet as an ICTV-supported, easily searchable database that includes all published virus names and abbreviations linked to their taxa is not available. In addition, in stark contrast to other biological taxonomic frameworks, virus taxonomy currently permits individual species to have several members. Consequently, confusion emerges among those who are not aware of the difference between taxa and viruses, and because certain well-known viruses cannot be located in ICTV publications or be linked to their species. In addition, the number of duplicate names and abbreviations has increased dramatically in the literature. To solve this conundrum, the ICTV could mandate listing all viruses of established species and all reported unclassified viruses in forthcoming online ICTV Reports and create a searchable webpage using this information. The International Union of Microbiology Societies could also consider changing the mandate of the ICTV to include the nomenclature of all viruses in addition to taxon considerations. With such a mandate expansion, official virus names and virus name abbreviations could be catalogued and virus nomenclature could be standardized. As a result, the ICTV would become an even more useful resource for all stakeholders in virology.
High sensitivity M‐protein detection in a case of light‐chain cardiac amyloidosis without evidence of plasma cell dyscrasia
Saadalla, Abdulrahman , Singh, Avinainder , Barnidge, David R. , Kohlhagen, Mindy , Merlini, Giampaolo , Falk, Rodney H. , Murray, David , Saadalla, Abdulrahman M , Barnidge, David, Merlini, Giampaolo , Falk, Rodney H

Mayo Clinic

American Journal of Hematology | December 21, 2018 | Volume: 94 | Issue: 5 | Pages: 619-621

10.1002/ajh.25383 | PMID 30575105 Get It

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes
Fang, Hong , Reichard, Kaaren K. , Rabe, Kari G. , Hanson, Curtis A. , Call, Timothy G. , Ding, Wei , Muchtar, Eli , Schwager, Susan M., Leis, José F., Chanan‐Khan, Asher , Braggio, Esteban , Smoley, Stephanie A., Shanafelt, Tait D. , Dyke, Daniel L. Van , Kenderian, Saad S. , Chanan-Khan, Asher A., Van Dyke, Daniel L, Chaffee, Kari G. , Ding, Wei , Muchtar, E , Shanafelt, Tait D , Braggio, Esteban , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

American Journal of Hematology | December 21, 2018 | Volume: 94 | Issue: 3 | Pages: 338-345

10.1002/ajh.25385 | PMID 30575108 Get It

The prevalence, clinicopathologic correlates, and outcomes of previously untreated chronic lymphocytic leukemia (CLL) patients with IGH‐BCL2 and IGH‐BCL3 translocations are not well known. Using the Mayo Clinic CLL database, we identified patients seen between March 1, 2002 and September 30, 2016 who had FISH testing performed within 3 years of CLL diagnosis. The prognostic profile, time to first therapy (TTT), and overall survival (OS) of patients with IGH‐BCL2 and IGH‐BCL3 translocation were compared to patients without these abnormalities (non‐IGH group). Of 1684 patients who met the inclusion criteria, 38 (2.2%) had IGH‐BCL2, and 16 (0.9%) had IGH‐BCL3 translocation at diagnosis. Patients with IGH‐BCL3 translocation were more likely to have high and very‐high CLL‐International Prognostic Index, compared to patients with IGH‐BCL2 translocation and the non‐IGH group. The 5‐year probability of requiring therapy was significantly higher for IGH‐BCL3 compared to IGH‐BCL2 and non‐IGH groups (84% vs 33% vs 29%, respectively, P < 0.0001). The 5‐year OS was significantly shorter for IGH‐BCL3 compared to IGH‐BCL2 and non‐IGH groups (45% vs 89% vs 86%, respectively, P < 0.0001). On multivariable analyses, IGH‐BCL3 translocation was associated with a shorter TTT (hazard ratio [HR] = 2.7; P = 0.005) and shorter OS (HR = 5.5; P < 0.0001); IGH‐BCL2 translocation did not impact TTT and OS. In conclusion, approximately 3% of all newly diagnosed CLL patients have either an IGH‐BCL2 or IGH‐BCL3 translocation. Patients with IGH‐BCL3 translocations have a distinct prognostic profile and outcome. These results support the inclusion of an IGH probe during the routine evaluation of FISH abnormalities in newly diagnosed CLL.
Racial Differences in Disease Presentation and Management of Intracranial Meningioma
Anzalone, C. Lane , Glasgow, Amy E. , Carlson, Matthew L. , Glasgow, Amy E. , Gompel, Jamie J. Van , Glasgow, Amy E

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | December 21, 2018 | Volume: 80 | Issue: 06 | Pages: 555-561

10.1055/s-0038-1676788 | PMID 31750040 Get It

Objective/Hypothesis The aim of the study was to determine the impact of race on disease presentation and treatment of intracranial meningioma in the United States. Study Design This study comprised of the analysis of a national population-based tumor registry. Methods Analysis of the surveillance, epidemiology, and end results (SEER) database was performed, including all patients identified with a diagnosis of intracranial meningioma. Associations between race, disease presentation, treatment strategy, and overall survival were analyzed in a univariate and multivariable model. Results A total of 65,973 patients with intracranial meningiomas were identified. Of these, 45,251 (68.6%) claimed white, 7,796 (12%) black, 7,154 (11%) Hispanic, 4,902 (7%) Asian, and 870 (1%) patients reported “other-unspecified” or “other-unknown.” The median annual incidence of disease was lowest among black (3.43 per 100,000 persons) and highest among white (9.52 per 100,000 persons) populations (p < 0.001). Overall, Hispanic patients were diagnosed at the youngest age and white patients were diagnosed at the oldest age (mean of 59 vs. 66 years, respectively; p < 0.001). Compared with white populations, black, Hispanic, and Asian populations were more likely to present with larger tumors (p < 0.001). After controlling for tumor size, age, and treatment center in a multivariable model, Hispanic patients were more likely to undergo surgery than white, black, and Asian populations. Black populations had the poorest disease specific and overall survival rates at 5 years following surgery compared with other groups. Conclusion Racial differences among patients with intracranial meningioma exist within the United States. Understanding these differences are of vital importance toward identifying potential differences in the biological basis of disease or alternatively inequalities in healthcare delivery or access Further studies are required to determine which factors drive differences in tumor size, age, annual disease incidence, and overall survival between races.
What Is the Optimal Placebo for Clinical Trials of Nerve Blocks in Headache?: An N‐of‐1 Study of Lactated Ringer’s
Potter, Jamie L., Robblee, Jennifer , Robblee, Jennifer V, Robblee, Jennifer V , Smith, Jonathan H.

Mayo Clinic

Headache: The Journal of Head and Face Pain | December 21, 2018 | Volume: 59 | Issue: 1 | Pages: 108-109

10.1111/head.13441 | PMID 30575969 Get It

Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis
Clifford, Katherine , Hobson‐Webb, Lisa D., Benatar, Michael , Burns, Ted M., Barnett, Carolina , Silvestri, Nicholas J. , Howard, James F. , Visser, Amy , Beekman, Rachel , Kumar, Aditya , Ruzhansky, Katherine , Chen, I-Hweii A. , Pulley, Michael , LaBoy, Shannon, Fellman, Melissa, Howard, Diantha B., Kolb, Noah , Greene, Shane M., Pasnoor, Mamatha , Dimachkie, Mazen M. , Hehir, Michael K. , Kumar, Aditya , Clifford, Katherine M , Crum, Brian A. , Kolb, Noah A , Dimachkie, Mazen M , Barnett-Tapia, Carolina , Nowak, Richard J. , Barohn, Richard J. , Beekman, Rachel B

Mayo Clinic

Muscle & Nerve | December 21, 2018 | Volume: 59 | Issue: 4 | Pages: 404-410

10.1002/mus.26404 | PMID 30575980 Get It

ABSTRACT Introduction : A randomized trial demonstrated benefit from thymectomy in nonthymomatous acetylcholine receptor (AChR)‐antibody positive myasthenia gravis (MG). Uncontrolled observational and histologic studies suggest thymectomy may not be efficacious in anti–muscle‐specific kinase (MuSK)‐MG. Methods : The therapeutic impact of thymectomy was evaluated from data collected for a multicenter, retrospective blinded review of rituximab in MuSK‐MG. Results : Baseline characteristics were similar between thymectomy ( n = 26) and nonthymectomy ( n = 29) groups, including treatment with rituximab (42% vs. 45%). At last visit, 35% of thymectomy subjects reached the primary endpoint, a Myasthenia Gravis Foundation of America (MGFA) post‐intervention status (PIS) score of minimal manifestations (MM) or better, compared with 55% of controls ( P = 0.17). After controlling for age at onset of MG, rituximab, prednisone, and intravenous immunoglobulin/plasma exchange treatment, thymectomy was not associated with greater likelihood of favorable clinical outcome (odds ratio = 0.43, 95% confidence interval 0.12–1.53, P = 0.19). Discussion : Thymectomy was not associated with additional clinical improvement in this multicenter cohort of MuSK‐MG patients. Muscle Nerve 59:404–410, 2019
VEGF receptor‐1 modulates amyloid β 1–42 oligomer‐induced senescence in brain endothelial cells
Wang, Ying , Wang, Enfeng , Pal, Krishnendu , Rosenberry, Terrone L. , Das, Pritam , Watzlawik, Jens O. , Pal, Krishnendu , Angom, Ramcharan Singh , Bhattacharya, Santanu , Mukhopadhyay, Debabrata , Wang, Ying

Mayo Clinic

The FASEB Journal | December 21, 2018 | Volume: 33 | Issue: 3 | Pages: 4626-4637

10.1096/fj.201802003r | PMID 30576228 Get It

ABSTRACT Aggregated amyloid β (Aβ) peptides in the Alzheimer's disease (AD) brain are hypothesized to trigger several downstream pathologies, including cerebrovascular dysfunction. Previous studies have shown that Aβ peptides can have antiangiogenic properties, which may contribute to vascular dysfunction in the early stages of the disease process. We have generated data showing that brain endothelial cells (ECs) exposed to toxic Aβ1‐42 oligomers can readily enter a senescence phenotype. To determine the effect of Aβ oligomers on brain ECs, we treated early passaged human brain microvascular ECs and HUVECs with high MW Aβ1‐42 oligomers (5 µM, for 72 h). For controls, we used no peptide treatment, 5 µM Aβ1‐42 monomers, and 5 µM Aβ1‐42 fibrils, respectively. Brain ECs treated with Aβ1‐42 oligomers showed increased senescence‐associated β‐galactosidase staining and increased senescence‐associated p21/ p53 expression. Treatment with either Aβ1‐42 monomer or Aβ1‐42 fibrils did not induce senescence in this assay. We then measured vascular endothelial growth factor receptor (VEGFR) expression in the Aβ1‐42 oligomer‐treated ECs, and these cells showed significantly increased VEGFR‐1 expression and decreased VEGFR‐2 levels. Overexpression of VEGFR‐1 in brain ECs readily induced senescence, suggesting a direct role of VEGFR‐1 signaling events in this paradigm. More importantly, small interfering RNA‐mediated knockdown of VEGFR‐1 expression in brain ECs was able to prevent up‐regulation of p21 protein expression and significantly reduced induction of senescence following Aβ1‐42 oligomer treatment. Our studies show that exposure to Aβ1‐42 oligomers may impair vascular functions by altering VEGFR‐1 expression and causing ECs to enter a senescent phenotype. Altered VEGFR expression has been documented in brains of AD patients and suggests that this pathway may play a role in AD disease pathogenesis. These studies suggest that modulating VEGFR‐1 expression and signaling events could potentially prevent senescence and rejuvenate EC functions, and provides us with a novel target to pursue for prevention and treatment of cerebrovascular dysfunction in AD.—Angom, R. S., Wang, Y., Wang, E., Pal, K., Bhattacharya, S., Watzlawik, J. O., Rosenberry, T. L., Das, P., Mukhopadhyay, D. VEGF receptor‐1 modulates amyloid β 1–42 oligomer‐induced senescence in brain endothelial cells. FASEB J. 33, 4626–4637 (2019). www.fasebj.org